FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3201135904> ?p ?o ?g. }

• W3201135904 endingPage "106482" @default.
• W3201135904 startingPage "106482" @default.
• W3201135904 abstract "20-60% of patients with initially locally advanced Renal Cell Carcinoma (RCC) develop metastatic disease despite optimal surgical excision. Adjuvant strategies have been tested in RCC including cytokines, radiotherapy, hormones and oral tyrosine-kinase inhibitors (TKIs), with limited success. The predominant global standard-of-care after nephrectomy remains active monitoring. Immune checkpoint inhibitors (ICIs) are effective in the treatment of metastatic RCC; RAMPART will investigate these agents in the adjuvant setting.RAMPART is an international, UK-led trial investigating the addition of ICIs after nephrectomy in patients with resected locally advanced RCC. RAMPART is a multi-arm multi-stage (MAMS) platform trial, upon which additional research questions may be addressed over time. The target population is patients with histologically proven resected locally advanced RCC (clear cell and non-clear cell histological subtypes), with no residual macroscopic disease, who are at high or intermediate risk of relapse (Leibovich score 3-11). Patients with fully resected synchronous ipsilateral adrenal metastases are included. Participants are randomly assigned (3,2:2) to Arm A - active monitoring (no placebo) for one year, Arm B - durvalumab (PD-L1 inhibitor) 4-weekly for one year; or Arm C - combination therapy with durvalumab 4-weekly for one year plus two doses of tremelimumab (CTLA-4 inhibitor) at day 1 of the first two 4-weekly cycles. The co-primary outcomes are disease-free-survival (DFS) and overall survival (OS). Secondary outcomes include safety, metastasis-free survival, RCC specific survival, quality of life, and patient and clinician preferences. Tumour tissue, plasma and urine are collected for molecular analysis (TransRAMPART).ISRCTN #: ISRCTN53348826, NCT #: NCT03288532, EUDRACT #: 2017-002329-39, CTA #: 20363/0380/001-0001, MREC #: 17/LO/1875, ClinicalTrials.gov Identifier: NCT03288532, RAMPART grant number: MC_UU_12023/25, TransRAMPART grant number: A28690 Cancer Research UK, RAMPART Protocol version 5.0." @default.
• W3201135904 created "2021-09-27" @default.
• W3201135904 creator A5003892243 @default.
• W3201135904 creator A5006392701 @default.
• W3201135904 creator A5009340780 @default.
• W3201135904 creator A5014097745 @default.
• W3201135904 creator A5015969462 @default.
• W3201135904 creator A5018620241 @default.
• W3201135904 creator A5023193867 @default.
• W3201135904 creator A5025529463 @default.
• W3201135904 creator A5025689357 @default.
• W3201135904 creator A5033091020 @default.
• W3201135904 creator A5039368541 @default.
• W3201135904 creator A5041398432 @default.
• W3201135904 creator A5041569289 @default.
• W3201135904 creator A5045032804 @default.
• W3201135904 creator A5046417678 @default.
• W3201135904 creator A5051124832 @default.
• W3201135904 creator A5051492539 @default.
• W3201135904 creator A5058223039 @default.
• W3201135904 creator A5061757629 @default.
• W3201135904 creator A5064732405 @default.
• W3201135904 creator A5066422299 @default.
• W3201135904 creator A5068678186 @default.
• W3201135904 creator A5074162105 @default.
• W3201135904 creator A5076054848 @default.
• W3201135904 creator A5077610703 @default.
• W3201135904 creator A5085499539 @default.
• W3201135904 creator A5090081649 @default.
• W3201135904 date "2021-09-01" @default.
• W3201135904 modified "2023-10-17" @default.
• W3201135904 title "RAMPART: A phase III multi-arm multi-stage trial of adjuvant checkpoint inhibitors in patients with resected primary renal cell carcinoma (RCC) at high or intermediate risk of relapse" @default.
• W3201135904 cites W1890294563 @default.
• W3201135904 cites W1988015039 @default.
• W3201135904 cites W2069480574 @default.
• W3201135904 cites W2099752220 @default.
• W3201135904 cites W2222086386 @default.
• W3201135904 cites W2264794294 @default.
• W3201135904 cites W2530419161 @default.
• W3201135904 cites W2594458845 @default.
• W3201135904 cites W2753065806 @default.
• W3201135904 cites W2756219586 @default.
• W3201135904 cites W2758082149 @default.
• W3201135904 cites W2792488818 @default.
• W3201135904 cites W2792937256 @default.
• W3201135904 cites W2896175597 @default.
• W3201135904 cites W2911812451 @default.
• W3201135904 cites W2913745075 @default.
• W3201135904 cites W2967350775 @default.
• W3201135904 cites W3008030961 @default.
• W3201135904 cites W3092785514 @default.
• W3201135904 cites W3119708965 @default.
• W3201135904 cites W3131063362 @default.
• W3201135904 cites W3134949580 @default.
• W3201135904 cites W3199995424 @default.
• W3201135904 cites W3201135904 @default.
• W3201135904 doi "https://doi.org/10.1016/j.cct.2021.106482" @default.
• W3201135904 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/8520913" @default.
• W3201135904 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/34538402" @default.
• W3201135904 hasPublicationYear "2021" @default.
• W3201135904 type Work @default.
• W3201135904 sameAs 3201135904 @default.
• W3201135904 citedByCount "30" @default.
• W3201135904 countsByYear W32011359042021 @default.
• W3201135904 countsByYear W32011359042022 @default.
• W3201135904 countsByYear W32011359042023 @default.
• W3201135904 crossrefType "journal-article" @default.
• W3201135904 hasAuthorship W3201135904A5003892243 @default.
• W3201135904 hasAuthorship W3201135904A5006392701 @default.
• W3201135904 hasAuthorship W3201135904A5009340780 @default.
• W3201135904 hasAuthorship W3201135904A5014097745 @default.
• W3201135904 hasAuthorship W3201135904A5015969462 @default.
• W3201135904 hasAuthorship W3201135904A5018620241 @default.
• W3201135904 hasAuthorship W3201135904A5023193867 @default.
• W3201135904 hasAuthorship W3201135904A5025529463 @default.
• W3201135904 hasAuthorship W3201135904A5025689357 @default.
• W3201135904 hasAuthorship W3201135904A5033091020 @default.
• W3201135904 hasAuthorship W3201135904A5039368541 @default.
• W3201135904 hasAuthorship W3201135904A5041398432 @default.
• W3201135904 hasAuthorship W3201135904A5041569289 @default.
• W3201135904 hasAuthorship W3201135904A5045032804 @default.
• W3201135904 hasAuthorship W3201135904A5046417678 @default.
• W3201135904 hasAuthorship W3201135904A5051124832 @default.
• W3201135904 hasAuthorship W3201135904A5051492539 @default.
• W3201135904 hasAuthorship W3201135904A5058223039 @default.
• W3201135904 hasAuthorship W3201135904A5061757629 @default.
• W3201135904 hasAuthorship W3201135904A5064732405 @default.
• W3201135904 hasAuthorship W3201135904A5066422299 @default.
• W3201135904 hasAuthorship W3201135904A5068678186 @default.
• W3201135904 hasAuthorship W3201135904A5074162105 @default.
• W3201135904 hasAuthorship W3201135904A5076054848 @default.
• W3201135904 hasAuthorship W3201135904A5077610703 @default.
• W3201135904 hasAuthorship W3201135904A5085499539 @default.
• W3201135904 hasAuthorship W3201135904A5090081649 @default.
• W3201135904 hasBestOaLocation W32011359041 @default.
• W3201135904 hasConcept C121608353 @default.
• W3201135904 hasConcept C126322002 @default.
• W3201135904 hasConcept C141071460 @default.

• next